To develop detection of glucose contrast enhancement (GCE) with CEST for assessing brain metastases in clinical setting, here we performed a phantom study, scanned 10 healthy volunteers and one patient with brain metastases at 3T. We acquired dynamic GCE at 1.2 and 2 ppm for dynamic B0 correction and applied principle component analysis (PCA) to perform noise reduction, after which we compared the resulting GCE at both offsets. The developed pipeline resulted in GCE of ~5% in tumor and -5 to 0.05% in healthy tissues after glucose infusion.
This abstract and the presentation materials are available to members only; a login is required.